The company will continue its focus on supporting laboratory research, and packaging for diagnostics and specialty
Millville, NJ, October 25, 2012 – WHEATON, the company that designs and delivers innovative solutions for the
laboratory research, diagnostic packaging and specialty pharmaceuticals industries, announced the appointment of
Wayne Brinster to the role of president. Mr. Brinster succeeds Stephen R, Drozdow, who remains as chief executive
officer. Mr. Brinster brings to the position a familiar, science-driven focus while sharing Mr. Drozdow’s long-time
commitment to WHEATON customers, suppliers, partner and employees.
Mr. Brinster comes to WHEATON from Synthon Pharmaceuticals, a privately owned manufacturer of pharmaceutical
and biopharmaceutical products, where he served as vice president and general manager. Prior to Synthon, Mr. Brinster
worked in different management roles for over 30 years at Becton, Dickinson and Company, where he most recently led
the BD Diagnostics Women’s Heath and Cancer.
"Having spent most of my life in the business of science, I am excited to be here with a leading name in the field, joining
an organization that has developed a reputation for supporting important scientific achievements," said Mr. Brinster. "By
leveraging technical knowledge with excellent customer service, we're going to continue placing WHEATON at the
forefront of the industry," he added.
Mr. Drozdow, after leading WHEATON since 1996, will become the chief executive officer and will continue to have an
active role at WHEATON, working closely with Mr. Brinster on matters pertaining to strategy, key industry relationships,
finance, budgets and acquisitions. "Wayne is a great business leader," said Mr. Drozdow. "He understands the science
of our markets, knows our industry and identifies with our approach to customers.